DSS (DSS) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 02, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-32146
Entity Registrant Name	DSS, INC.
Entity Central Index Key	0000771999
Entity Tax Identification Number	16-1229730
Entity Incorporation, State or Country Code	NY
Entity Address, Address Line One	275 Wiregrass Pkwy
Entity Address, City or Town	West Henrietta
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14586
City Area Code	585
Local Phone Number	325-3610
Title of 12(b) Security	Common Stock, $0.02 par value per share
Trading Symbol	DSS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		84,626,847

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 53,811,000	$ 56,595,000
Accounts receivable, net	6,103,000	5,673,000
Inventory	9,778,000	10,380,000
Current portion of notes receivable	6,739,000	6,310,000
Prepaid expenses and other current assets	1,869,000	3,466,000
Total current assets	78,300,000	82,424,000
Property, plant and equipment, net	16,247,000	17,674,000
Investment in real estate, net	56,365,000	56,374,000
Other investments	10,466,000	11,001,000
Investment, equity method	1,193,000	1,080,000
Marketable securities	18,435,000	14,172,000
Notes receivable	6,240,000	5,878,000
Other assets	557,000	489,000
Right-of-use assets	1,181,000	498,000
Goodwill	56,606,000	56,606,000
Other intangible assets, net	36,269,000	38,630,000
Total assets	281,859,000	284,826,000
Current liabilities:
Accounts payable	2,452,000	1,920,000
Accrued expenses and deferred revenue	16,515,000	21,180,000
Other current liabilities	402,000	402,000
Current portion of lease liability	540,000	393,000
Current portion of long-term debt, net	6,835,000	3,916,000
Total current liabilities	26,744,000	27,811,000
Long-term debt, net	59,398,000	55,711,000
Long term lease liability	782,000	120,000
Other long-term liabilities	880,000	880,000
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, $.02 par value; 47,000 shares authorized, shares issued and outstanding (47,000 on December 31, 2021); Liquidation value $1,000 per share, $46,868,000 aggregate December 31, 2021).
Common stock, $.02 par value; 200,000,000 shares authorized, 84,626,847 shares issued and outstanding (79,745,886 on December 31, 2021)	1,692,000	1,594,000
Additional paid-in capital	296,450,000	294,685,000
Non-controlling interest in subsidiaries	36,345,000	36,409,000
Accumulated deficit	(140,432,000)	(132,384,000)
Total stockholders’ equity	194,055,000	200,304,000
Total liabilities and stockholders’ equity	$ 281,859,000	$ 284,826,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.02	$ 0.02
Preferred stock, shares authorized	47,000	47,000
Preferred stock, shares issued	47,000	47,000
Preferred stock, shares outstanding	47,000	47,000
Preferred stock, liquidation preference per share		$ 1,000
Preferred stock, liquidation preference, value		$ 46,868,000
Common stock, par value	$ 0.02	$ 0.02
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	84,626,847	79,745,886
Common stock, shares outstanding	84,626,847	79,745,886

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 12,304,000	$ 4,469,000
Costs and expenses:
Cost of revenue, exclusive of depreciation and amortization	5,443,000	3,287,000
Selling, general and administrative (including stock based compensation)	10,338,000	4,060,000
Depreciation and amortization	3,266,000	514,000
Total costs and expenses	19,047,000	7,861,000
Operating loss	(6,743,000)	(3,392,000)
Other income (expense):
Interest income	156,000	52,000
Other income	(1,703,000)
Interest expense	(1,378,000)	(20,000)
Gain on extinguishment of debt		116,000
Loss on equity method investment	(112,000)	(579,000)
(Gain) loss on investments	424,000	(1,077,000)
Gain on sale of asset	405,000
Loss from continuing operations before income taxes	(8,951,000)	(4,900,000)
Income tax benefit		838,000
Loss from continuing operations	(8,951,000)	(4,062,000)
Income from discontinued operations, net of tax		50,000
Net loss	(8,951,000)	(4,012,000)
(Gain) loss from continuing operations attributed to noncontrolling interest	903,000	31,000
Net loss attributable to common stockholders	$ (8,048,000)	$ (3,981,000)
Loss per common share:
Basic	$ (0.10)	$ (0.21)
Diluted	(0.10)	(0.21)
Earnings per common share - discontinued operations:
Basic
Diluted
Shares used in computing loss per common share:
Basic	84,626,847	19,432,831
Diluted	84,626,847	19,432,831
Printed Products [Member]
Revenue:
Total revenue	$ 3,569,000	$ 3,861,000
Rental Income [Member]
Revenue:
Total revenue	1,663,000
Management Fee Income [Member]
Revenue:
Total revenue	11,000
Net Investment Income [Member]
Revenue:
Total revenue	129,000
Direct Marketing [Member]
Revenue:
Total revenue	$ 6,932,000	$ 608,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss from continuing operations	$ (8,951,000)	$ (4,062,000)
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities:
Depreciation and amortization	3,266,000	514,000
Stock based compensation	4,000	12,000
Loss on equity method investment	(112,000)	579,000
Loss (gain) on investments	424,000	1,076,000
Impairment of notes receivable and other investments	1,637,000
Gain on extinguishment of debt		(116,000)
Deferred tax benefit		(838,000)
Decrease (increase) in assets:
Accounts receivable	(430,000)	82,000
Inventory	602,000	(601,000)
Prepaid expenses and other current assets	1,597,000	(103,000)
Other assets	(68,000)	(382,000)
Increase (decrease) in liabilities:
Accounts payable	532,000	107,000
Accrued expenses	(4,697,000)	(3,521,000)
Other liabilities	126,000	(778,000)
Net cash used by operating activities	(6,070,000)	(8,031,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(942,000)	(72,000)
Purchase of real estate		(3,230,000)
Purchase of investment	(1,085,000)	(4,329,000)
Purchase of marketable securities	(4,693,000)	2,188,000
Disposal of property, plant and equipment	2,152,000
Note receivable investment	(791,000)	(1,006,000)
Net cash used by investing activities	(5,359,000)	(6,449,000)
Cash flows from financing activities:
Payments of long-term debt	(246,000)	(89,000)
Borrowings of long-term debt	6,193,000	110,000
Debt conversion to equity in subsidiary	840,000
Issuances of common stock, net of issuance costs	1,858,000	61,068,000
Net cash provided by financing activities	8,645,000	61,089,000
Cash flows from discontinued operations:
Cash (used) provide by discontinued operations		(12,000)
Net cash used by discontinued operations		(12,000)
Net increase (decrease) in cash	(2,784,000)	46,597,000
Cash and cash equivalents at beginning of period	56,595,000	5,226,000
Cash and cash equivalents at end of period	$ 53,811,000	$ 51,823,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Non- controlling Interest in Subsidiary [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 116,000	$ 1,000	$ 174,380,000	$ 3,430,000	$ (101,382,000)	$ 76,545,000
Balance, shares at Dec. 31, 2020	5,836,000	43,000
Issuance of common stock, net	$ 436,000		60,632,000			61,068,000
Issuance of common stock, net, shares	21,834,000
Stock based payments, net of tax effect			15,000			15,000
Net loss				(31,000)	(3,981,000)	(4,012,000)
Ending balance, value at Mar. 31, 2021	$ 552,000	$ 1,000	235,027,000	3,399,000	(105,363,000)	133,616,000
Balance, shares at Mar. 31, 2021	27,670,000	43,000
Beginning balance, value at Dec. 31, 2021	$ 1,594,000		294,686,000	36,407,000	(132,384,000)	200,304,000
Balance, shares at Dec. 31, 2021	79,746,000
Issuance of common stock, net	$ 98,000		1,760,000			1,858,000
Issuance of common stock, net, shares	4,881,000
Conversion of debt to equity in subsidiary				840,000		840,000
Stock based payments, net of tax effect			4,000			4,000
Net loss				(903,000)	(8,048,000)	(8,951,000)
Ending balance, value at Mar. 31, 2022	$ 1,692,000		$ 296,450,000	$ 36,344,000	$ (140,432,000)	$ 194,055,000
Balance, shares at Mar. 31, 2022	84,627,000

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies The Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS” and updated its CUSIP number to 26253C 102. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”) currently operates nine (9) distinct business lines with operations and locations around the globe. These business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct Marketing, (4) Commercial Lending, (5) Securities and Investment Management, (6) Alternative Trading (7) Digital Transformation, (8) Secure Living, and (9) Alternative Energy. Each of these business lines are in different stages of development, growth, and income generation. Our divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. (3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific, Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Bancorp (“APB”), is organized for the purposes of being a financial network holding company, focused on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. (6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications and operations processes with custom software development and implementation. (8) The Secure Living division has developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology, energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential housing. (9) The Alternative Energy group was established to help lead the Company’s future in the clean energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide underutilized properties with small microgrids for independent energy. On August 21, 2020, the Company, completed its acquisition of Impact BioMedical, Inc. (“Impact BioMedical”), pursuant to a Share Exchange Agreement by and among the Company, DSS BioHealth Security, Inc. (“DSS BioHealth”), Alset International Limited (formally Singapore eDevelopment Ltd.), and Global Biomedical Pte Ltd. (“GBM”), which was previously approved by the Company’s shareholders (the “Share Exchange”). Under the terms of the Share Exchange, the Company issued 483,334 shares of the Company’s common stock, par value $ 0.02 per share, valued at $ 6.48 per share, and 46,868 newly issued shares of the Company’s Series A Convertible Preferred Stock (“Series A Preferred Stock”). As a result of the Share Exchange, Impact BioMedical is now a wholly owned subsidiary of DSS BioHealth, the Company’s wholly owned subsidiary (see Note 5). Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of its partners, Impact BioMedical has undertaken a concerted effort in the research and development (“R&D”), drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. On September 9, 2021, the Company finalized a stock purchase agreement (the “SPA”) with American Pacific Bancorp, Inc. (“APB”), which provided for an investment of $ 40,000,200 by the Company into APB for an aggregate of 6,666,700 shares of the APB’s Class A Common Stock, par value $ 0.01 per share. Subject to the terms and conditions contained in the SPA, the shares issued at a purchase price of $ 6.00 per share. As a result of this transaction, DSS became the majority owner of APB. (see Note 5). On September 13, 2021, the Company finalized a shareholder agreement between its subsidiary, DSS Financial Management, Inc. (“DFMI”) and HR1 Holdings Limited (“HR1”), a company incorporated in the British Virgin Islands, for the purpose of operating a vehicle for private and institutional investors seeking a highly liquid investment fund with attractive risk adjusted returns relative to market unpredictability and volatility. Under the terms of this agreement, 4000 shares or 40% of the Company’s subsidiary Liquid Asset Limited Management Limited (“LVAM”), a Hong Kong company was transferred to HR1 whereas at the conclusion of the transaction DFMI would own 60% of LVAM and HR1 would own 40% . LVAM executes within reliable platforms and broad market access and uses proprietary systems and algorithms to trade liquid exchange-traded funds (ETFs), stocks, futures or crypto. Aimed at providing consistent returns while offering the unique ability to liquidate the portfolio within 5 to 10 minutes under normal market conditions, LVAM provides an array of advanced tools and products enabling customers to explore multiple opportunities, strengthen and diversify their portfolios, and meet their individual investing goals. On December 23, 2021, DSS purchased 50,000,000 shares at $ 0.06 per share of Sharing Services Global Corporation (“SHRG”) via a private placement. With this purchase, DSS increased its ownership of voting shares from approximately 47% of SHRG to approximately 58 %. SHRG aims to build shareholder value by developing or acquiring businesses that increase the Company’s product and services portfolio, business competencies and geographic reach . Currently, the Company, through its subsidiaries, markets and distributes its health and wellness and other products primarily in the United States, Canada, and the Asia Pacific region using a direct selling business model. SHRG markets its products and services through its independent sales force, using its proprietary websites, including: www.elevacity.com and www.thehappyco.com. SHRG, headquartered in Plano, Texas, was incorporated in the State of Nevada on April 24, 2015, and is an emerging growth company. SHRG Common Stock is traded, under the symbol “SHRG,” in the OTCQB Market, an over-the-counter trading platforms market operated by OTC Markets Group Inc. The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly our consolidated financial position as of March 31, 2022 and December 31, 2021, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K for the fiscal year ended December 31, 2021 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). Principles of Consolidation - The consolidated financial statements include the accounts of DSS, Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates Reclassifications Cash Equivalents Notes receivable, unearned interest, and related recognition Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments. Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Inventory – Inventories consist primarily of paper, pre-printed security paper, paperboard, fully prepared packaging, and health and beauty products which and are stated at the lower of cost or net realizable value on the first-in, first-out (“FIFO”) method. Packaging work-in-process and finished goods included the cost of materials, direct labor and overhead. At the closing of each reporting period, the Company evaluates its inventory in order to adjust the inventory balance for obsolete and slow-moving items. An allowance for obsolescence of approximately $ 22,000 388,000 associated with the inventory at our SHRG subsidiary was recorded as of March 31, 2022, and December 31, 2021, respectively. Write-downs and write-offs are charged to cost of revenue. Impairment of Long-Lived Assets and Goodwill Acquisitions Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations. Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition and all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill. If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded. The application of business combination accounting requires the use of significant estimates and assumptions. Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information. (Loss) Earnings Per Common Share - The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share reflect the actual weighted average of shares issued and outstanding during the period. Diluted (loss) earnings per share are computed including the number of additional shares from outstanding warrants, stock options and preferred stock that would have been outstanding if dilutive potential shares had been issued and is calculated utilizing the treasury stock method. In a loss period, the calculation for basic and diluted (loss) earnings per share is the same, as the impact of potential common shares is anti-dilutive. For the three months ended 31, 2022, potential dilutive instruments includes both warrants and options of 3,556 11,930 29,314 13,596 43,000 6,570,000 Concentration of Credit Risk - During the three months ended March 31, 2022, two customers accounted for 10 3 % of our consolidated revenue. As of March 31, 2022, these two customers accounted for 29 6 of our consolidated trade accounts receivable balance. During the three months ended March 31, 2021, these two customers accounted for 31 8 % of our consolidated revenue and 57 % and 8 of our consolidated trade accounts receivable balance. Income Taxes Recent Accounting Pronouncements

Revenue

Revenue	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	2. Revenue The Company recognizes its products and services revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, net of amortization of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. The Company recognizes net investment income from its investment banking line of business as interest owed to the Company occurs. The Company generates revenue from its direct marketing line of business primarily through internet sales and recognizes revenue as items are shipped. As of March 31, 2022, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Accounts Receivable The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally does not require collateral. Payment terms are generally 30 days but up to net 105 for certain customers. The Company carries its trade accounts receivable at invoice amount less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts based upon management’s estimates that include a review of the history of past write-offs and collections and an analysis of current credit conditions. At March 31, 2022, and December 31, 2021, the Company established a reserve for doubtful accounts of approximately $ 70,000 20,000 Sales Commissions Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of March 31, 2022. Shipping and Handling Costs Costs incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers pertaining to these costs are reflected as revenue. See Note 13 for disaggregated revenue information.

Notes Receivable

Notes Receivable	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Notes Receivable	3. Notes Receivable American Premium Water Corporation On October 15, 2020, APB entered into a loan agreement with (“APW Note”) with American Premium Water Corporation,(“APW”), a Nevada corporation. The loan, not to exceed the principal sum of $ 200,000 12 October 15, 2022 39,000 GSX Group Limited On February 8, 2021, the Company entered into a convertible promissory note (“GSX Note”) with GSX Group Limited (“GSX”), a company registered in Gibraltar. The Company loaned the principal sum of $ 800,000 , with principal and interest at a rate of 4 %, due in one year from date of issuance. The outstanding principal and interest as of March 31, 2022 and December 31, 2021, approximated $ 837,000 and $ 829,000 , respectively, and is classified as a Current portion of notes receivable on the Consolidated Balance Sheets at December 31, 2021. GSX repaid the principal and interest in full in April 2022. On February 3, 2021, USX Holdings Company, Inc., a subsidiary of the Company entered into a binding joint venture term sheet (“GSX JV”), along with Coinstreet, whose CEO is also a member of the Company’s board of directors, for the creation of a USA based joint venture alternative trading system or exchange (“JV Exchange”). During the nine-months ended September 30, 2021, the Company and GSX finalized the terms of the JV Exchange. This JV is currently in the planning stages. Dustin Crum On February 21, 2021, Impact BioMedical, Inc. a subsidiary of the Company, entered into a promissory note (“Crum Note”) with Dustin Crum (“Mr. Crum”). The Company loaned the principal sum of $ 206,000 6.5 207,000 Sentinel Brokers Company, Inc. On May 13, 2021, Sentinel Brokers, LLC, a subsidiary of the Company entered a revolving credit promissory note (“Sentinel Note”) with Sentinel Brokers Company, Inc. (“Sentinel”), a company registered in the state of New York. The Sentinel Note has an aggregate principal balance up to $ 600,000 , to be funded at request of Sentinel. The Sentinel Note, which incurs interest at a rate of 6.65 % is payable in areas until the principal is paid in full at the maturity date of May 13, 2023 . As of March 31, 2022 and December 31, 2021, there was $ 151,000 and $ 0 , respectively, outstanding on the Sentinel Note, and is included in current notes receivable on the accompanying consolidated balance sheet. Also on May 13, 2021, the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 % equity position of Sentinel for the purchase price of $ 300,000 . During April 2022, the Sentinel Note was amended to increase the available revolving credit principal to $ 3,000,000 . See Note 6. Puradigm, LLC On May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered into a convertible promissory note (“Puradigm Note”) with Puradigm, LLC (“Puradigm”), a company registered in the state of Texas. The Puradigm Note has an aggregate principal balance up to $ 5,000,000 , to be funded at request of Puradigm. The Puradigm Note, which incurs interest at a rate of 6.5 % due quarterly, has a maturity date of May 14, 2023 . The Puradigm Note contains an options conversion clause that allows the Company to convert all, or a portion of all, into new issued member units of Puradigm with the maximum principal amount equal to 18% of the total equity position of Puradigm at conversion. The outstanding principal and interest as of March 31, 2022 and December 31, 2021, approximated $ 5,164,000 and $ 5,081,000 , respectively, which is classified as Notes receivable on the consolidated balance sheet. South Regional Management District (formally Harris-Montgomery Counties Management District) On September 23, 2021, APB entered into refunding bond anticipatory note (“District Note”) with South Regional Management District (the “District”), which operates as a conservation and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code; Chapter 375, Texas Local Government Code; and Chapter 49, Texas Water Code. The District Note was in the sum of $ 3,500,000 and incurs interest at a rate of 4.15 % per annum. Principal and interest are due in full on September 22, 2022 . This note may be redeemed prior to maturity with 10 days written notice to APB at a price equal to principal plus interest accrued on the redemption date . The outstanding principal and interest of $ 3,576,000 and $ 3,540,000 of the District Note is included in current portion of notes receivable on the consolidated balance sheet at March 31, 2022 and December 31, 2021, respectively. Asili, LLC. On October 25, 2021, APB entered into loan agreements (“Asili Agreement”) with Asili, LLC. (“Asili”) a company registered in the state of Utah. The Asili Agreement has an initial aggregate principal balance up to $ 1,000,000 , to be funded at request of Asili, with an option to increase the maximum principal borrowing to $ 3,000,000 . The Asili Agreement, which incurs interest at a rate of 8.0 % with principal and interest due at the maturity date of October 25, 2022 . The Asili Agreement contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. APB, as holder of the Asili Agreement, has the right to elect one member to the Asili Board of Managers . The outstanding principal and interest of approximately $ 803,000 and $ 784,000 of the Asili Agreement is included in current portion of notes receivable on the consolidated balance sheet at March 31, 2022 and December 31, 2021, respectively. Leopoldo Bustamate. On June 13, 2019, APB extended the credit to Leopoldo Bustamate (“Bustamate Note”) in the form of a promissory note for $ 249,540 , bearing interest at 15 %, with a maturity date of May 15, 2020 . On June 5, 2020, the Company further extended the same credit in the form of a promissory note for $ 249,540 , bearing interest at 15 %, with a maturity date of May 14, 2021 . On August 30, 2021, the Company further extended the same credit in the form of a promissory note for $ 249,540 , bearing interest at 12.5 %, with a maturity date of May 15, 2023 . The modification agreement is effective May 14, 2021. This promissory note is secured by a deed of trust on a tract of land, which is approximately 315 acres, and located in Coke County, Texas. The outstanding principal and interest of approximately $ 289,000 of the Bustamate Note is included in long term portion of Notes receivable on the consolidated balance sheet at March 31, 2022 and December 31, 2021. HWH World Ltd. On October 7, 2021, HWH World, Inc., a subsidiary of the Company entered into a revolving loan commitment (“HWH Ltd Note”) with HWH World Ltd. (“HWH Ltd.”) a company registered in Taiwan. The HWH Ltd. Note has an principal balance of $ 52,000 and incurred no interest through the maturity date of December 31,2021 . The outstanding principal at March 31, 2022 and December 31, 2021 is $ 56,000 and $ 52,000 , respectively, and is included in the current portion of notes receivable. This note is currently in default and the Company is currently in the process of extending the terms. In accordance with the terms of the HWH Ltd. Note, the Company began charging interest at the default rate of 18 % on January 1, 2022 . West Park Capital Group, LLC. On December 28, 2021, APB entered into promissory note (“West Park Note”) with West Park Capital Group, LLC. (“West Park”), a company registered in the state of California. The West Park Note has an principal balance of $ 700,000 12.0 December 28, 2022 680,000 700,000 1044PRO, LLC. In January 2021, SHRG and 1044PRO, LLC (“1044 PRO”) entered into a Funding Agreement pursuant to which the Company agreed to provide to 1044 PRO a $ 250,000 revolving credit line and loaned $ 204,879 to 1044 PRO under the credit line. Borrowings under the credit line are payable in monthly installments in amounts determined by the amount of each cash advance. At December 31, 2021, loans of $ 193,000 are outstanding, net of an allowance for the impairment losses of $ 115,000 , and is included in Current portion of notes receivable on the consolidated balance sheet as of December 31, 2021. At March 31, 2022, this loan was fully reserved for. In connection with the loan, the Company acquired a 10 % equity interest in 1044 PRO and a security interest in 1044 PRO’s cash receipts and in substantially all 1044 PRO’s assets. XIP Optimal In the fiscal year 2019, SHRG received a promissory note for $ 106,404 from a prior merchant payment processor in connection with amounts owed to the Company. This note is fully reserved for at March 31, 2022, and December 31, 2021. WUURII Commerce Inc., On March 2, 2022, APB and WUURII Commerce, Inc. (“WUURRII”), a corporation organized under the laws of the Republic of Korea entered into a promissory note (“WUURRII Note”). Under the terms of the WURRII Note, APB at its discretion, may lend up to the principal sum of $ 892,500 with an interest rate of 8 %, and matures in March 2024, with interest payable quarterly. The outstanding principal and interest at March 31, 2022 is $ 895,000 , of which $ 446,000 Farah S. Khan On January 24, 2022, APB and Farah S. Khan (“Khan”) entered into a promissory note (“Khan Note”) in the principal sum of $ 100,000 with interest of 6 %, due annually, and maturing in January 2024. The outstanding principal and interest at March 31, 2022 approximates $ 101,000 , and is included in notes receivable on the accompanying consolidate balance sheet.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2022
Investments, All Other Investments [Abstract]
Financial Instruments	4. Financial Instruments Cash, Cash Equivalents, Restricted Cash and Marketable Securities The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of March 31, 2022, and December 31, 2021: Schedule of Cash and Marketable Securities by Significant Investment Category 2022 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 48,799,000 $ - $ 48,799,000 $ 48,799,000 $ - $ - Level 1 Money Market Funds 5,012,000 - 5,012,000 5,012,000 - - Marketable Securities 15,865,000 2,570,000 18,435,000 - 18,435,000 - Level 2 Warrants 3,318,000 - 3,318,000 - - 3,318,000 Convertible securities 1,023,000 357,000 1,380,000 - - 1,380,000 Total $ 74,017,000 $ 2,927,000 $ 76,944,000 $ 53,811,000 $ 18,435,000 $ 4,698,000 2021 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 50,286,000 $ - $ 50,286,000 $ 50,286,000 $ - $ - Level 1 Money Market Funds $ 6,309,000 - 6,309,000 6,309,000 - - Marketable Securities $ 12,993,000 1,544,000 14,537,000 - 14,537,000 - Level 2 Warrants $ 3,318,000 - 3,318,000 - - 3,318,000 Convertible securities $ 1,023,000 - 1,023,000 - - 1,023,000 Total $ 73,929,000 $ 1,544,000 $ 75,473,000 $ 56,595,000 $ 14,537,000 $ 4,341,000 The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	5. Acquisitions American Medical REIT Inc. On March 3, 2020, the Company, via its subsidiary DSS Securities, entered into a share subscription agreement and loan arrangement with LiquidValue Asset Management Pte Ltd., AMRE Asset Management, Inc. and American Medical REIT Inc. under which it acquired a 52.5 93 AMRE entered into a $ 200,000 unsecured promissory note with LiquidValue Asset Management Pte Ltd (“LVAMPTE”). The Note calls for interest to be paid annually on March 2 with interest fixed at 8.0 %. See Note 7 for further details. LVAMPTE is majority owned subsidiary of Alset International Limited whose Chief Executive Office and largest shareholder is Heng Fai Ambrose Chan, the Chairman of the Board and largest shareholder of the Company. On June 18, 2021, DSS Securities, entered into a stock purchase agreement with AMRE to acquire 264,525 10 2,645,250 264,525 93 On June 18, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE financed the purchase of a 40,000 square foot, 2.0 story, Class A+ multi-tenant medical office building located on a 13.62-acre site in Shelton, Connecticut (See Note 7) for the purchase price of $ 7,150,000 . In accordance with Topic 805, the acquisition of the medical facility has been determined to be an acquisition of assets as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. These assets are classified as investments, real estate on the consolidated balance sheet. The purchase price has been allocated as $ 4,640,000 , $ 1,600,000 , and $ 325,000 for the facility, land and tenant improvements respectively. Also include in the value of the property is $ 585,000 of intangible assets with an estimated useful life approximating 3 years . All assets were allocated on a relative fair value basis. Contained within the sale-purchase agreement for this facility, is a $ 1,500,000 earnout due to the seller if certain criteria are met. As of March 31, 2022, no liability has been recorded for this earnout as it isn’t probable the earnout will be achieved as of the quarter-end On November 4, 2021, AMRE LifeCare Portfolio, LLC. (“AMRE LifeCare”), a subsidiary of AMRE, acquired three medical facilities located in Fort Worth, Texas, Plano, Texas, and Pittsburgh, Pennsylvania for a purchase price of $ 62,000,000 32,100,000 12,100,000 1,500,000 15,901,000 1 11 On December 21, 2021, AMRE Winter Haven, LLC. (“AMRE Winter Haven”), a subsidiary of AMRE, acquired a medical facility located in Winter Haven, Florida for a purchase price of $ 4,500,000 3,200,000 1,000,000 222,000 29,000 5 years During the three-months ended March 31, 2022, and 2021, AMRE had net losses of $ 1,613,000 and $ 58,000 , respectively, of which $ 161,000 and $ 22,000 , respectively is attributable to non-controlling interest. Impact BioMedical, Inc. Impact BioMedical, a wholly owned subsidiary of the Company, has several subsidiaries that are not wholly owned by Impact Biomedical and have an ownership percentage ranging from 63.6 % to 100 %. During the three months ended March 31, 2022, and 2021, Impact Biomedical has incurred approximately $ 614,000 and $ 420,000 respectively of net losses, of which $ 67,000 and $ 9,000 respectively of loss incurred is attributable to non-controlling interest. American Pacific Bancorp. On September 9, 2021, the Company finalized a stock purchase agreement (the “SPA”) with American Pacific Bancorp (“APB”), which provided for an investment of $ 40,000,000 by the Company into APB for an aggregate of 6,666,700 shares of the APB’s Class A Common Stock, par value $ 0.01 per share. Subject to the terms and conditions contained in the SPA, the shares issued at a purchase price of $ 6.00 per share. As a result of this transaction, DSS owns approximately 53 % of APB, and as a result its operating results will be included in the Company’s financial statements beginning September 9, 2021. The Company incurred approximately $ 36,000 in cost associated with the acquisition of APB which were recorded as general and administrative expenses. The acquisition of APB meets the definition of a business with inputs, processes and outputs, and therefore, the Company has concluded to account for this transaction in accordance with the acquisition method of accounting under Topic 805. During the three months ended March 31, 2022, APB had net income of $ 547,000 , of which, $ 257,000 is attributable to non-controlling interest. The next largest shareholder of APB is Alset EHome International, Inc. (“AEI”). AEI’s Chairman and CEO, Heng Fai Ambrose Chan, and a member of the AEI’s Board of Directors, Wu Wai Leung William, each serve on both the AEI Board and the Board of the Company. The CEO of the Company, Mr. Frank D. Heuszel, also has an approximate 2 % equity position of APB. APB and the company in which APB owns marketable securities share a common director. Sharing Services Global Corp. (“SHRG”) As of and through June 30, 2020, the Company classified its investment in Sharing Services Global Corp. (“SHRG”), a publicly traded company, as marketable equity security and measured it at fair value with gains and losses recognized in other income. In July 2020, through continued acquisition of common stock, as detailed below, the Company obtained greater than 20 % ownership of SHRG, and thus has the ability to exercise significant influence over it. During the quarter ended September 30, 2020, the Company began to account for its investment in SHRG using the equity method in accordance with ASC Topic 323, Investments—Equity Method and Joint Ventures 58 58 On January 24, 2022, the Company exercised 50,000,000 warrants received as part of a consulting agreement with SHRG at the exercise price of $ 0.0001 , bring its ownership percentage of voting shares to approximately 65% . The acquisition of SHRG meets the definition of a business with inputs, processes, and outputs, and therefore, the Company has concluded to account for this transaction in accordance with the acquisition method of accounting under Topic 805. During the three months ended March 31, 2022, SHRG incurred $ 7,364,000 of losses of which, $ 2,579,000 is attributed to non-controlling interest. We are currently in the process of completing the purchase price accounting and related allocations associated with the acquisition of SHRG. The Company is in the process of completing valuations and useful lives for certain assets acquired in the transaction. We expect the preliminary purchase price accounting to be completed during the year ending December 31, 2022.

Investments

Investments	3 Months Ended
	Mar. 31, 2022
Investments, All Other Investments [Abstract]
Investments	6. Investments Alset International Limited The Company owns 127,179,311 shares or approximately 7 % of the outstanding shares of Alset International Limited (“Alset Intl”), formerly named Singapore eDevelopment Limited (“SED”), a company incorporated in Singapore and publicly listed on the Singapore Exchange Limited. This investment is classified as a marketable security and is classified as long-term assets on the consolidated balance sheets as the Company has the intent and ability to hold the investments for a period of at least one year. The Chairman of the Company, Mr. Heng Fai Ambrose Chan, is the Executive Director and Chief Executive Officer of Alset Intl. Mr. Chan is also the majority shareholder of Alset Intl as well as the largest shareholder of the Company. The fair value of the marketable security as of March 31, 2022, and December 31, 2021, was approximately $ 4,604,000 and $ 4,909,000 respectively. During the three months ended March 31, 2022 and March 31, 2021, the Company recorded unrealized loss on this investment of approximately $ 305,000 967,000 Century TBD Holdings, LLC On October 10, 2019, the Company entered into a convertible promissory note (“TBD Note”) with Century TBD Holdings, LLC (“TBD”), a Florida limited liability company. The Company loaned the principal sum of $ 500,000 500,000 19.8 6 October 9, 2021 537,000 7.5 500,000 37,000 BMI Capital International LLC On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9 100,000 10 24.9 20 49,000 BMIC is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s chairman of the board and another independent board member of the Company also have ownership interest in BMIC. Alset Title Company On or about August 28, 2020, the Company’s wholly owned subsidiary, DSS Securities, Inc. entered into a corporate venture to form and operate a real estate title agency, under the name of Alset Title Company, Inc, a Texas corporation (“ATC”). DSS Securities, Inc. shall own 70% of this venture with the other two shareholders being attorneys necessary to the state application and permitting process. ATC have initiated or have pending applications to do business in a number of states, including Texas, Tennessee, Connecticut, Florida, and Illinois. For the purpose of organization and the state application process, the Company’s CEO, who is a licensed attorney, has a stated non-compensated 15% ownership interest in the venture. There was minimal activity for the three months ended March 31, 2022 BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 ordinary shares or 4.99 % of BioMed at a purchase price of approximately $ 632,000 . The Subscription Agreement provides, among other things, the Company has the right to appoint a new director to the board of BioMed. With respect to an issuance of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary tag-along rights. In connection with the Subscription Agreement, Impact Biomedical entered into an exclusive distribution agreement (the “Distribution Agreement”) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing natural probiotics, to resellers. This investment is valued at cost as it does not have a readily determined fair value. BioMed focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell certain BioMed products to resellers. The products to be distributed by the Company include BioMed’s PGut Premium Probiotics ® ® ® ® ® Under the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States, Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with a one year auto-renewal feature. Vivacitas Oncology, Inc. On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 shares of its common stock at the per share price of $ 1.00 , with an option to purchase 1,500,000 additional shares at the per share price of $ 1.00 . This option will terminate upon one of the following events: (i) Vivacitas’ board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii) the date on which Vivacitas receives more than $ 1.00 per share of the Company’s common stock in a private placement with gross proceeds of $ 500,000 . Under the terms of the Vivacitas Agreement #1, the Company will be allocated two seats on the board of Vivacitas. On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (“Seller”) to purchase from the Seller’s its wholly owned subsidiary Impact Oncology PTE Ltd. (“IOPL”) for a purchase price $ 2,480,000 . The acquisition of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic 805. IOPL owns 2,480,000 shares of common stock of Vivacitas along with the option to purchase an additional 250,000 shares of common stock. The Sellers largest shareholder is Mr. Heng Fai Ambrose Chan, the Chairman of the Company’s board of directors and its largest shareholder. On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021 and March 31, 2022. On July 22, 2021, the Company exercised 1,000,000 1,000,000 16 Sentinel Brokers Company, Inc. On May 13, 2021, a Sentinel Brokers, LLC., subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 300,000 750,000 1,050,000 50.1 25 50.1 24.9 Investments—Equity Method and Joint Ventures Sentinel is a broker-dealer operating primarily as a fiduciary intermediary, facilitating intuitional trading of municipal and corporate bonds as well as preferred stock, and is registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). Stemtech Corporation In September 2021, SHRG, Stemtech Corporation (“Stemtech”) and Globe Net Wireless Corp. (“GNTW”) entered into a Securities Purchase Agreement (the “SPA”) pursuant to which the SHRG invested $ 1.4 million in Stemtech in exchange for: (a) a Convertible Promissory Note in the amount of $ 1.4 million in favor of the SHRG (the “Convertible Note”) and (b) a detachable Warrant to purchase shares of GNTW common stock (the “GNTW Warrant”). Stemtech is a subsidiary of GNTW. As an inducement to enter into the SPA, GNTW agreed to pay to the SHRG an origination fee of $ 500,000 , payable in shares of GNTW’s common stock. The Convertible Note matures on September 9, 2024 , bears interest at the annual rate of 10 %, and is convertible, at the option of the holder, into shares of GNTW’s common stock at a conversion rate calculated based on the closing price per share of GNTW’s common stock during the 30-day period ended September 19, 2021. . In September 2021, GNTW issued to the SHRG 154,173 shares of its common stock, or less than 1% of the shares of GNTW then issued and outstanding, in payment of the origination fee. SHRG carries its investment in the Convertible Note, the GNTW Warrant and the shares of GNTW common stock at fair value in accordance with U.S. GAAP. During the three month ended March 31, 2022 and twelve months ended December 31, 2021, the SHRG recognized unrealized gains, before income tax, of $ 357,000 and $ 3,700,000 , respectively, in connection with its investment in the Convertible Note, the GNTW Warrant and the shares of GNTW common stock. MojiLife, LLC In September 2021, SHRG entered into a Membership Unit Purchase Agreement pursuant to which the SHRG acquired a 30.75 % equity interest in MojiLife, LLC, a limited liability company, organized in the State of Utah, in exchange for $ 1,537,000 . MojiLife is an emerging growth distributor of technology-based consumer products, such as cordless scent diffusers, for the home and the car, as well as proprietary home cleaning products and accessories. During the three months ended March 31, 2022, SHRG recognized an impairment of this investment approximating $ 1,500,000

Short-Term and Long-Term Debt

Short-Term and Long-Term Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Short-Term and Long-Term Debt	7. Short-Term and Long-Term Debt DSS, Inc Promissory Notes - 200,000 unsecured promissory note with LVAMPTE. The Note calls for interest to be paid annually on March 2 with interest fixed at 8.0 %. As further incentive to enter into this Note, AMRE granted LVAMPTE warrants to purchase shares of common stock of AMRE (the “Warrants”). The amount of the warrants granted is the equivalent of the Note Principal divided by the Exercise Price. The Warrants are exercisable for four years and are exercisable at $ 5.00 per share (the “Exercise” Price). In March 2022, this debt was converted into equity in AMRE, and LVAMPTE exercised the warrants for $ 200,000 The holder is a related party owned by the Chairman of the Company’s board of directors. On March 16, 2021, American Medical REIT, Inc. received loan proceeds in the amount of approximately $ 110,000 under the Paycheck Protection Program (“PPP”) with a fixed rate of 1 % and a 60-month maturity term. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. These funds were used for payroll, benefits, rent, mortgage interest, and utilities. As of March 31, 2022, and December 31, 2021, the outstanding principal and interest approximated $ 111,000 is included in long-term debt, net on the consolidated balance sheet. On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with Bank of America, N.A. (“BOA”) to secure financing approximating $ 3,700,000 to purchase a new Heidelberg XL 106-7+L printing press. The aggregate principal balance outstanding under the BOA Note shall bear interest at a variable rate on or before the loan closing. At closing, the interest rate shall be fixed for the duration of the Loan. As of March 31, 2022, and December 31, 2021, the outstanding principal on the BOA Note was $ 3,710,000 and $ 3,339,000 , respectively and had an interest rate of 4.63 %, and is included in Long-term debt, net on the consolidated balance sheet. The BOA Note contains certain covenants that are analyzed annual. As of March 31, 2022, Premier is in compliance with these covenants. On June 18, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $ 6,155,000 , with the amount financed approximating $ 5,105,000 . The Shelton Agreement contains monthly payments of principal and an initial interest 4.25 %. The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25 % for the term of 120 months with a balloon payment approximating $ 2,829,000 due at term end. This agreement contains certain covenants that are analyzed on an annual basis, starting December 31, 2021, of which, AMRE Shelton is in compliance as of March 31, 2022 The funds borrowed were used to purchase a 40,000 square foot, 2.0 story, Class A+ multi-tenant medical office building located on a 13.62 acre site (See Note 5). Of the total financed, approximately $ 191,000 is classified as current portion of long-term debt, net, and the remaining balance of approximately $ 4,799,000 recorded as long-term debt, net of $ 185,000 in deferred financing costs. On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), whereas LVAM borrowed the principal amount of $ 3,000,000 , with interest to be charged at a variable rate to be adjusted at the maturity date . The BMIC Loan matures on October 12, 2022 , and contains an auto renewal period of three months. As of Mach 31, 2022 and December 31, 2021, $ 3,021,000 3,000,000 is included in current portion of long-term debt, net on the consolidated balance sheet. On October 13, 2021, LVAM entered into loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 3,000,000 On November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank, (“Pinnacle Bank”) in the amount of $ 40,300,000 . The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five ( 25 ) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28 %, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full. The maturity date of November 2, 2023, may be extended to November 2, 2024. As of December 31, 2021, the outstanding principal and interest of the LifeCare agreement approximates $ 39,448,000 , net of deferred financing costs of $ 1,002,000 . As of March 31, 2022, the outstanding principal and interested approximates $ 39,940,000 and is included in long-term debt, net on the consolidated balance sheet. AMRE is currently seeking from Pinnacle, and believes it will obtain, a waiver on certain debt covenants. In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”) for the principal amount of $ 8,350,000 8 December 2023 8,688,000 On March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $ 2,990,000 March 7, 2024 4.28 138,000 2,857,000 Sharing Services Global Corporation In October 2017, SHRG issued a Convertible Promissory Note in the principal amount of $ 50,000 (the “Note”) to HWH International, Inc (“HWH International” or the “Holder”). HWH International is affiliated with Heng Fai Ambrose Chan, who became a Director of SHRG April 2020. The Note is convertible into 333,333 shares of SHRG Common Stock. Concurrent with issuance of the Note, SHRG issued to HWH International a detachable warrant to purchase up to an additional 333,333 shares of SHRG Common Stock, at an exercise price of $ 0.15 per share. Under the terms of the Note and the detachable stock warrant, the Holder is entitled to certain financing rights. If SHRG enters into more favorable transactions with a third-party investor, it must notify the Holder and may have to amend and restate the Note and the detachable stock warrant to be identical. In December 2019, SHRG and the holder of the SHRG $ 100,000 convertible note dated April 13, 2018 (the “April 2018Note”) entered into an amendment to the underlying promissory note. Pursuant to the amendment, the parties extended the maturity date of the note to April 2021. In addition, after giving effect to the amendment, the April 2018 Note is non-interest bearing. All other terms of the April 2018 Note remain unchanged. This Note was repaid in full during March 2022.

Lease Liability

Lease Liability	3 Months Ended
	Mar. 31, 2022
Lease Liability
Lease Liability	8 . Lease Liability The Company has operating leases predominantly for operating facilities. As of March 31, 2022, the remaining lease terms on our operating leases range from less than one five years Future minimum lease payments as of March 31, 2022, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2022 513,000 2023 775,000 2024 54,000 2025 4,000 2026 2,000 2027 - After - Total lease payments 1,348,000 Less: Imputed Interest (26,000 ) Present value of remaining lease payments $ 1,322,000 Current $ 540,000 Noncurrent $ 782,000 Weighted-average remaining lease term (years) 3.5 Weighted-average discount rate 4.2 % In March of 2022, Premier Packaging began leasing its relocated manufacturing facilities to West Henrietta, New York. This lease contains an escalating payment clause, ranging from $ 61,000 78,000

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies The Ronaldi Litigation In April 2019 DSS commenced an action in New York State Supreme Court, Monroe County, Index No. E2019003542, against Jeffrey Ronaldi, our former Chief Executive Officer. This New York action seeks a declaratory judgment that, contrary to informal claims made by him, Mr. Ronaldi’s employment agreement with us expired by its terms and that he is not entitled to any cash bonuses or other unpaid amounts. The lawsuit also seeks an injunction against Mr. Ronaldi from interfering with any of DSS’ IP litigation. Mr. Ronaldi subsequently commenced an action against DSS in the Superior Court of California, County of San Diego, on November 8, 2019, under case number 37-2019-00059664-CU-CO-CTL, in which he alleged that DSS terminated his employment in April 2019 in order to avoid paying him certain employment-related amounts. DSS was successful in dismissing the California case and consolidating it with the action pending in Monroe County, New York. Mr. Ronaldi asserted counterclaims in the Monroe County, New York action similar to those he originally brought in California. Mr. Ronaldi claims that his termination violated an alleged employment agreement or implied-in-fact employment agreement and that he should have remained employed through 2019. Mr. Ronaldi seeks to recover: (i) $144,658 in wages from April 11, 2019 through December 31, 2019; (ii) $769 in alleged unpaid based salary for time worked before April 11, 2019; (iii) $15,385 in alleged paid time off compensation; (iv) $3,077 in alleged unpaid sick time compensation; (v) $26,077 in waiting-time penalties; (vi) $91,000 in unspecified expense reimbursement; (vii) $300,000 in alleged cash bonuses ($100,000 per year) based on DSS’s performance in 2017, 2018 and 2019; and (viii) a $450,000 performance bonus based on the result of certain alleged net proceeds from patent infringement litigation. He further claims an interest in any recovery in DSS Technology Management v. Apple, Inc., Case No. 4:14-cf05330-HSG. The court recently ordered Mr. Ronaldi to produce several categories of documents that he sought to withhold. Discovery is ongoing Additionally, on March 2, 2020, DSS and DSSTM filed a second litigation action against Jeffrey Ronaldi in the State of New York, Supreme Court, County of Monroe, Document Security Systems, Inc. and DSS Technology Management, Inc. vs. Jeffrey Ronaldi, Index No.: 2020002300, alleging acts of self-dealing and conflicts of interest while he served as CEO of both DSS and DSS TM. Mr. Ronaldi filed a Notice of Removal of this civil litigation to the United States District Court for the Western District of New York where it was assigned Case No. 6:20-cv-06265-EAW. Mr. Ronaldi filed a motion seeking to compel DSS to advance his legal fees to defend the action, which motion was fully briefed as of June 30, 2020, and remains pending and undecided. On March 16, 2021, the Western District of New York granted Mr. Ronaldi’s motion to have his defense costs advanced to him during the pendency of the action as they are incurred. On March 26, 2021, Mr. Ronaldi applied to the court for reimbursement of $ 160,896.25 in legal fees which was subsequently reduced to $ 159,771.25 . A second application was filed on November 12, 2021, seeking $ 121,672.51 in fees for a total demand of $ 281,443.76 . The Company has objected to the size of those bills as they were based on out-of-town billing rates and the result of an excessive number of hours spent on litigation. The parties now engaged in discovery, awaiting a decision on the Company’s objection to Mr. Ronaldi’s fee applications. The parties engaged in court-ordered mediation on June 17, 2021, but the matter did not resolve. Following mediation, the Company moved to stay the federal court action pending the outcome of the state court action to avoid inconsistent rulings on common issues of law and fact. The motion to stay was denied. The Company intends to vigorously prosecute this action. Maiden Biosciences Litigation On February 15, 2021, Maiden Biosciences, Inc. (“Maiden”) commenced an action against DSS, Inc. (“DSS”), Decentralized Sharing Systems, Inc. (“Decentralized”), HWH World, Inc. (“HWH”), RBC Life International, Inc., RBC Life Sciences, Inc (“RBC”)., Frank D. Heuszel (“Heuszel”), Steven E. Brown, Clinton Howard, and Andrew Howard (collectively, “Defendants”). The lawsuit is currently pending in the United States District Court Northern District of Texas, Dallas Division, and is styled and numbered Maiden Biosciences, Inc. v. Document Security Stems, Inc., et al., Case No. 3:21-cv-00327. This lawsuit relates to two promissory notes executed by RBC in the 4 th 2019 in favor of Decentralized and HWH, totaling approximately $800,000. Maiden, a 2020 default judgment creditor of RBC, in the principal amount of $4,329,000, now complains about those notes, the funding of those notes, the subsequent default of those notes by RBC, and HWH and Decentralized’s subsequent Article 9 foreclosure or deed-in-lieu debt conveyances. In the instant lawsuit, Maiden asserts claims against Defendants for unjust enrichment, fraudulent transfer under the Texas Uniform Fraudulent Transfer Act, and violation of the Racketeer Influenced and Corrupt Organizations Act. Maiden also seeks a judgment from the court declaring: “(1) Defendants lacked a valid security interest in RBC and RBC Subsidiaries’ assets and therefore lacked the authority to sell the assets during the public foreclosure sale; (2) Defendant Heuszel’s low bid at the public foreclosure sale was invalid and void; (3) the public foreclosure sale was conducted in a commercially unreasonable manner; and (4) Defendants do not have the legal authority to transfer RBC and RBC’s Subsidiaries assets to Heuszel and HWH.” Maiden seeks to recover from Defendants: (1) treble damages or, alternatively, damages in the amount of their underlying judgment plus the other creditors’ claims or the value of the assets transferred, whichever is less, plus punitive or exemplary damages; (2) pre- and post-judgment interest; and (3) attorneys’ fees and cost . On March 30, 2021, Defendants DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel filed a motion to dismiss seeking to dismiss Maiden’s unjust enrichment, exemplary damages, and RICO claims against DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel, as well as Maiden’s fraudulent transfer claims against DSS and RBC International, Inc. On August 9, 2021, the Court then entered an order granting in part the motion to dismiss filed on behalf of DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel. Among other things, the Court held that Maiden failed to plausibly plead certain causes of action, including (1) the civil RICO claim against DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel, (2) the TUFTA claim against DSS, and (3) the unjust enrichment claim against DSS and RBC Life International, Inc. Notably, the Court declined the request to dismiss the TUFTA claim against RBC Life International, Inc. The Court granted Maiden leave to file an amended complaint. Maiden’s deadline to do so is Monday, September 6, 2021. The Company intends to vigorously defend its position. On September 3, 2021, Maiden filed its amended complaint, asserting a single cause of action against the DSS Defendants and RBC for an alleged TUFTA violation. Generally, Maiden is seeking the same relief requested in its original complaint. Maiden, however, has abandoned its request for treble damages. On September 17, 2021, the DSS Defendants filed a motion to dismiss the amended complaint seeking to dismiss Maiden’s TUFTA claim to the extent it seeks to avoid a transfer of assets owned by any of RBC’s subsidiaries, including but not limited to RBC Life Sciences USA, Inc. Further, the motion to dismiss also seeks the dismissal of Maiden’s TUFTA claim against Heuszel. The DSS Defendants’ motion to dismiss the amended complaint will be ripe for determination on or after October 22, 2021. Trial is currently set for December 5, 2022, on the Court’s two-week docket. In addition to the foregoing, we may become subject to other legal proceedings that arise in the ordinary course of business and have not been finally adjudicated. Adverse decisions in any of the foregoing may have a material adverse effect on our results of operations, cash flows or our financial condition. The Company accrues for potential litigation losses when a loss is probable and estimable.

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Equity	10. Stockholders’ Equity Sales of Equity On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase 44,619,423 shares of the Company’s common stock for a purchase price of $ 0.3810 per share, for an aggregate purchase price of $ 17,000,000 . Pursuant to the Amendment, the number of shares of the common stock of the Company that the AEI will purchase has been reduced to 3,986,877 shares for an aggregate purchase price of $ 1,519,000 . This transaction was completed on March 9, 2022. In addition, the Company’s Executive Chairman and a significant stockholder, Heng Fai Ambrose Chan, is the Chairman, Chief Executive Officer and largest shareholder of AEI. On March 10, 2022, the Company issued 894,084 340,000 Stock-Based Compensation - 4,000 .01

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	11. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the three-months ended March 31, 2022, and 2021: Schedule of Supplemental Cash Flow Information 2022 2021 Cash paid for interest $ 1,378,000 $ 20,000 Non-cash investing and financing activities: Termination of right of use lease asset $ - $ (744,000 ) Termination of right of use lease liability $ - $ 744,000 Debt conversion to equity $ 840,000 $ - Shares issued for accrued bonus $ 340,000 $ -

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	12. Segment Information The Company’s nine businesses lines are organized, managed and internally reported as five Our segment structure presented below represents a change from the prior year for the inclusion of our Biotechnology, Securities, and Commercial Lending segments and the removal of our Plastics segment, Digital Group and IP Technology Management segment as the Plastics segment was discontinued in 2020, DSS Digital was sold and discontinued in May 2021 and activities surrounding our IP Technology Management segment have significantly decreased. The amounts for these segments have been included in the Corporate reporting segment for the year ended March 31, 2022 and 2021, as necessary, below for reconciliation purposes. Approximate information concerning the Company’s operations by reportable segment for the three months ended March 31, 2022 and 2021 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended March 31, 2022 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,569,000 $ 129,000 $ 6,932,000 $ - $ 1,674,000 $ - $ 12,304,000 Depreciation and amortization 180,000 - 49,000 278,000 2,685,000 74,000 3,266,000 Interest expense 24,000 - 687,000 - 667,000 - 1,378,000 Stock based compensation 1,000 - - - - 3,000 4,000 Impairment of goodwill - - - - - - - Net income (loss) from continuing operations (42,000 ) 181,000 (4,486,000 ) (616,000 ) (2,508,000 ) (1,480,000 ) (8,951,000 ) Capital expenditures 923,000 - 2,000 - 13,000 4,000 942,000 Identifiable assets 23,371,000 57,259,000 45,788,000 56,276,000 85,178,000 13,987,000 281,859,000 Three Months Ended March 31,2021 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,861,000 $ $ 608,000 $ - $ - $ - $ 4,469,000 Depreciation and amortization 116,000 - 44,000 278,000 - 76,000 514,000 Interest expense 19,000 - - - - 1,000 20,000 Stock based compensation 1,000 - - - - 6,000 7,000 Impairment of goodwill - - - - - Net income (loss) from continuing operations 218,000 - (1,799,000 ) (698,000 ) - (1,783,000 ) (4,062,000 ) Capital expenditures 66,000 - 6,000 - - - 72,000 Identifiable assets 22,567,000 - 18,892,000 51,158,000 - 49,206,000 141,823,000 The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information: Three months ended March 31, 2022 Packaging Printing and Fabrication $ 3,516,000 Commercial and Security Printing 53,000 Total Printed Products $ 3,569,000 Three months ended March 31, 2021 Packaging Printing and Fabrication $ 3,720,000 Commercial and Security Printing 141,000 Total Printed Products $ 3,861,000 Direct Marketing Three months ended March 31, 2022 Direct Marketing Internet Sales $ 6,932,000 Total Direct Marketing $ 6,932,000 Three months ended March 31, 2021 Direct Marketing Internet Sales $ 608,000 Total Direct Marketing $ 608,000 Rental Income Three months ended March 31, 2022 Rental income $ 1,663,000 Total Rental Income $ 1,663,000 Three months ended March 31, 2021 Rental income $ - Total Rental Income $ - Management Fee Income Three months ended March 31, 2022 Management fee income $ 11,000 Total Management fee income $ 11,000 Three months ended March 31, 2021 Management fee income $ - Total Management fee income $ - Net Investment Income Three months ended March 31, 2022 Net investment income $ 129,000 Total Management fee income $ 129,000 Three months ended March 31, 2021 Management fee income $ - Total Management fee income $ -

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On April 29, 2022, a purported shareholder of the Company filed a lawsuit in the New York Supreme Court in Monroe County (the “Complaint”) against the Company and members of the Company’s Board. In general, the Complaint alleges that the defendants breached their fiduciary duty to defendant with regards to the transactions described in proposals 1 and 2 in our definitive proxy statement. The Company believes that the claims asserted in the above-described actions are without merit and that no supplemental disclosure is required under applicable law. However, in order to moot the unmeritorious disclosure claims, to avoid the risk of the above-described actions delaying or adversely affecting the transactions and to minimize the costs, risks and uncertainties inherent in litigation, without admitting any liability or wrongdoing, the Company has determined to voluntarily supplement its proxy statement. The plaintiff has withdrawn a request for hearing on their order to show cause to enjoin us from going forward on our proxy proposals 1 and 2.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation - The consolidated financial statements include the accounts of DSS, Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates
Reclassifications	Reclassifications
Cash Equivalents	Cash Equivalents
Notes receivable, unearned interest, and related recognition	Notes receivable, unearned interest, and related recognition
Investments	Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost.
Inventory	Inventory – Inventories consist primarily of paper, pre-printed security paper, paperboard, fully prepared packaging, and health and beauty products which and are stated at the lower of cost or net realizable value on the first-in, first-out (“FIFO”) method. Packaging work-in-process and finished goods included the cost of materials, direct labor and overhead. At the closing of each reporting period, the Company evaluates its inventory in order to adjust the inventory balance for obsolete and slow-moving items. An allowance for obsolescence of approximately $ 22,000 388,000 associated with the inventory at our SHRG subsidiary was recorded as of March 31, 2022, and December 31, 2021, respectively. Write-downs and write-offs are charged to cost of revenue.
Impairment of Long-Lived Assets and Goodwill	Impairment of Long-Lived Assets and Goodwill
Acquisitions	Acquisitions Business combinations and non-controlling interests are recorded in accordance with FASB ASC 805 Business Combinations. Under the guidance, the assets and liabilities of the acquired business are recorded at their fair values at the date of acquisition and all acquisition costs are expensed as incurred. The excess of the purchase price over the estimated fair values is recorded as goodwill. If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed, then a gain on acquisition is recorded. The application of business combination accounting requires the use of significant estimates and assumptions. Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information.
(Loss) Earnings Per Common Share	(Loss) Earnings Per Common Share - The Company presents basic and diluted (loss) earnings per share. Basic (loss) earnings per share reflect the actual weighted average of shares issued and outstanding during the period. Diluted (loss) earnings per share are computed including the number of additional shares from outstanding warrants, stock options and preferred stock that would have been outstanding if dilutive potential shares had been issued and is calculated utilizing the treasury stock method. In a loss period, the calculation for basic and diluted (loss) earnings per share is the same, as the impact of potential common shares is anti-dilutive. For the three months ended 31, 2022, potential dilutive instruments includes both warrants and options of 3,556 11,930 29,314 13,596 43,000 6,570,000
Concentration of Credit Risk	Concentration of Credit Risk - During the three months ended March 31, 2022, two customers accounted for 10 3 % of our consolidated revenue. As of March 31, 2022, these two customers accounted for 29 6 of our consolidated trade accounts receivable balance. During the three months ended March 31, 2021, these two customers accounted for 31 8 % of our consolidated revenue and 57 % and 8 of our consolidated trade accounts receivable balance.
Income Taxes	Income Taxes
Recent Accounting Pronouncements	Recent Accounting Pronouncements

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, All Other Investments [Abstract]
Schedule of Cash and Marketable Securities by Significant Investment Category	The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of March 31, 2022, and December 31, 2021: Schedule of Cash and Marketable Securities by Significant Investment Category 2022 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 48,799,000 $ - $ 48,799,000 $ 48,799,000 $ - $ - Level 1 Money Market Funds 5,012,000 - 5,012,000 5,012,000 - - Marketable Securities 15,865,000 2,570,000 18,435,000 - 18,435,000 - Level 2 Warrants 3,318,000 - 3,318,000 - - 3,318,000 Convertible securities 1,023,000 357,000 1,380,000 - - 1,380,000 Total $ 74,017,000 $ 2,927,000 $ 76,944,000 $ 53,811,000 $ 18,435,000 $ 4,698,000 2021 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 50,286,000 $ - $ 50,286,000 $ 50,286,000 $ - $ - Level 1 Money Market Funds $ 6,309,000 - 6,309,000 6,309,000 - - Marketable Securities $ 12,993,000 1,544,000 14,537,000 - 14,537,000 - Level 2 Warrants $ 3,318,000 - 3,318,000 - - 3,318,000 Convertible securities $ 1,023,000 - 1,023,000 - - 1,023,000 Total $ 73,929,000 $ 1,544,000 $ 75,473,000 $ 56,595,000 $ 14,537,000 $ 4,341,000

Lease Liability (Tables)

Lease Liability (Tables)	3 Months Ended
	Mar. 31, 2022
Lease Liability
Schedule of Future Minimum Lease Payments	Schedule of Future Minimum Lease Payments Totals 2022 513,000 2023 775,000 2024 54,000 2025 4,000 2026 2,000 2027 - After - Total lease payments 1,348,000 Less: Imputed Interest (26,000 ) Present value of remaining lease payments $ 1,322,000 Current $ 540,000 Noncurrent $ 782,000 Weighted-average remaining lease term (years) 3.5 Weighted-average discount rate 4.2 %

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following table summarizes supplemental cash flows for the three-months ended March 31, 2022, and 2021: Schedule of Supplemental Cash Flow Information 2022 2021 Cash paid for interest $ 1,378,000 $ 20,000 Non-cash investing and financing activities: Termination of right of use lease asset $ - $ (744,000 ) Termination of right of use lease liability $ - $ 744,000 Debt conversion to equity $ 840,000 $ - Shares issued for accrued bonus $ 340,000 $ -

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Operations by Reportable Segment	Approximate information concerning the Company’s operations by reportable segment for the three months ended March 31, 2022 and 2021 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended March 31, 2022 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,569,000 $ 129,000 $ 6,932,000 $ - $ 1,674,000 $ - $ 12,304,000 Depreciation and amortization 180,000 - 49,000 278,000 2,685,000 74,000 3,266,000 Interest expense 24,000 - 687,000 - 667,000 - 1,378,000 Stock based compensation 1,000 - - - - 3,000 4,000 Impairment of goodwill - - - - - - - Net income (loss) from continuing operations (42,000 ) 181,000 (4,486,000 ) (616,000 ) (2,508,000 ) (1,480,000 ) (8,951,000 ) Capital expenditures 923,000 - 2,000 - 13,000 4,000 942,000 Identifiable assets 23,371,000 57,259,000 45,788,000 56,276,000 85,178,000 13,987,000 281,859,000 Three Months Ended March 31,2021 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,861,000 $ $ 608,000 $ - $ - $ - $ 4,469,000 Depreciation and amortization 116,000 - 44,000 278,000 - 76,000 514,000 Interest expense 19,000 - - - - 1,000 20,000 Stock based compensation 1,000 - - - - 6,000 7,000 Impairment of goodwill - - - - - Net income (loss) from continuing operations 218,000 - (1,799,000 ) (698,000 ) - (1,783,000 ) (4,062,000 ) Capital expenditures 66,000 - 6,000 - - - 72,000 Identifiable assets 22,567,000 - 18,892,000 51,158,000 - 49,206,000 141,823,000
Schedule of Disaggregation of Revenue	The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information: Three months ended March 31, 2022 Packaging Printing and Fabrication $ 3,516,000 Commercial and Security Printing 53,000 Total Printed Products $ 3,569,000 Three months ended March 31, 2021 Packaging Printing and Fabrication $ 3,720,000 Commercial and Security Printing 141,000 Total Printed Products $ 3,861,000 Direct Marketing Three months ended March 31, 2022 Direct Marketing Internet Sales $ 6,932,000 Total Direct Marketing $ 6,932,000 Three months ended March 31, 2021 Direct Marketing Internet Sales $ 608,000 Total Direct Marketing $ 608,000 Rental Income Three months ended March 31, 2022 Rental income $ 1,663,000 Total Rental Income $ 1,663,000 Three months ended March 31, 2021 Rental income $ - Total Rental Income $ - Management Fee Income Three months ended March 31, 2022 Management fee income $ 11,000 Total Management fee income $ 11,000 Three months ended March 31, 2021 Management fee income $ - Total Management fee income $ - Net Investment Income Three months ended March 31, 2022 Net investment income $ 129,000 Total Management fee income $ 129,000 Three months ended March 31, 2021 Management fee income $ - Total Management fee income $ -

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 23, 2021	Sep. 13, 2021	Sep. 09, 2021	Aug. 21, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Oct. 31, 2017
Product Information [Line Items]
Common Stock, Par or Stated Value Per Share					$ 0.02		$ 0.02
Shares Issued, Price Per Share								$ 0.15
Inventory adjustments					$ 22,000		$ 388,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer A [Member]
Product Information [Line Items]
Concentration risk percentage					10.00%	31.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer B [Member]
Product Information [Line Items]
Concentration risk percentage					3.00%	8.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer A [Member]
Product Information [Line Items]
Concentration risk percentage					29.00%	57.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer B [Member]
Product Information [Line Items]
Concentration risk percentage					6.00%	8.00%
Warrant [Member]
Product Information [Line Items]
Anti-dilutive securities excluded from computation of EPS					3,556	29,314
Share-Based Payment Arrangement, Option [Member]
Product Information [Line Items]
Anti-dilutive securities excluded from computation of EPS					11,930	13,596
Convertible Preferred Stock [Member]
Product Information [Line Items]
Anti-dilutive securities excluded from computation of EPS						43,000
Stock conversion, shares issued						6,570,000
Impact BioMedical, Inc. [Member] | Share Exchange Agreement [Member]
Product Information [Line Items]
Stock Issued During Period, Shares, Acquisitions				483,334
Common Stock, Par or Stated Value Per Share				$ 0.02
Shares Issued, Price Per Share				$ 6.48
Impact BioMedical, Inc. [Member] | Share Exchange Agreement [Member] | Series A Preferred Stock [Member]
Product Information [Line Items]
Stock Issued During Period, Shares, New Issues				46,868
American Pacific Bancorp [Member]
Product Information [Line Items]
Stock Issued During Period, Shares, New Issues			6,666,700
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned			$ 40,000,000
Business Acquisition, Share Price			$ 6
Equity Method Investment, Ownership Percentage			2.00%
American Pacific Bancorp [Member] | Common Class A [Member]
Product Information [Line Items]
Common Stock, Par or Stated Value Per Share			$ 0.01
American Pacific Bancorp [Member] | Stock Purchase Agreement [Member]
Product Information [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned			$ 40,000,200
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			6,666,700
Business Acquisition, Share Price			$ 6
American Pacific Bancorp [Member] | Stock Purchase Agreement [Member] | Common Class A [Member]
Product Information [Line Items]
Common Stock, Par or Stated Value Per Share			$ 0.01
Liquid Asset Limited Management Limited [Member] | Stock Purchase Agreement [Member]
Product Information [Line Items]
Business Acquisition, Description of Acquired Entity		Under the terms of this agreement, 4000 shares or 40% of the Company’s subsidiary Liquid Asset Limited Management Limited (“LVAM”), a Hong Kong company was transferred to HR1 whereas at the conclusion of the transaction DFMI would own 60% of LVAM and HR1 would own 40%
Sharing Services Global Corp [Member]
Product Information [Line Items]
Equity Method Investment, Description of Principal Activities					On December 23, 2021, DSS purchased 50,000,000
Stock Repurchased During Period, Shares	50,000,000
Share Price	$ 0.06
Equity Method Investment, Ownership Percentage	58.00%

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 70,000	$ 20,000

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)

Dec. 28, 2021

Oct. 25, 2021

Oct. 07, 2021

Sep. 23, 2021

Aug. 30, 2021

May 14, 2021

May 13, 2021

Oct. 15, 2020

Jun. 05, 2020

Jun. 13, 2019

Jan. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Apr. 30, 2022

Mar. 02, 2022

Jan. 24, 2022

Dec. 31, 2021

Dec. 13, 2021

Jun. 18, 2021

Feb. 21, 2021

Feb. 08, 2021

Dec. 31, 2019

Oct. 31, 2017

Debt interest rate

4.25%

Debt instrument, face amount

$ 6,155,000

$ 50,000

Gain (Loss) on Extinguishment of Debt

$ 116,000

Maximum [Member]

Debt instrument, face amount

$ 5,105,000

Asili Agreement [Member]

Debt interest rate

8.00%

Maturity date

Oct. 25, 2022

Notes receivable

803,000

$ 784,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 3,000,000

Debt Instrument, Description

The Asili Agreement contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. APB, as holder of the Asili Agreement, has the right to elect one member to the Asili Board of Managers

Asili Agreement [Member] | Maximum [Member]

Debt instrument, face amount

$ 1,000,000

Sentinel Brokers Company Inc [Member]

Debt interest rate

6.65%

Sentinel Brokers Company Inc [Member]

Equity Method Investment, Ownership Percentage

24.90%

Puradigm LLC [Member] | Convertible Promissory Note [Member]

Maturity date

May 14, 2023

Sharing Services Global Corporation [Member]

Debt instrument, face amount

$ 106,404

Convertible Promissory Note [Member]

Outstanding principal and interest

3,576,000

3,540,000

Convertible Promissory Note [Member] | Sentinel Brokers Company Inc [Member]

Maturity date

May 13, 2023

Notes receivable

$ 600,000

151,000

$ 0

Business Combination, Consideration Transferred

$ 300,000

Convertible Promissory Note [Member] | American Premium Water Corporation [Member]

Outstanding principal and interest

$ 200,000

39,000

39,000

Debt interest rate

12.00%

Maturity date

Oct. 15, 2022

Convertible Promissory Note [Member] | GSX Group Limited [Member]

Outstanding principal and interest

837,000

829,000

$ 800,000

Debt interest rate

4.00%

Convertible Promissory Note [Member] | Dustin Crum [Member]

Outstanding principal and interest

207,000

$ 206,000

Debt interest rate

6.50%

Convertible Promissory Note [Member] | Puradigm LLC [Member]

Outstanding principal and interest

$ 5,000,000

$ 5,164,000

5,081,000

Debt interest rate

6.50%

Sentinel Note [Member] | Subsequent Event [Member]

Long-Term Line of Credit

$ 3,000,000

District Note [Member]

Debt interest rate

4.15%

Maturity date

Sep. 22, 2022

Debt instrument, face amount

$ 3,500,000

Debt Instrument, Redemption, Description

This note may be redeemed prior to maturity with 10 days written notice to APB at a price equal to principal plus interest accrued on the redemption date

Leopoldo Bustamate [Member]

Debt interest rate

12.50%

15.00%

15.00%

Maturity date

May 15, 2023

May 14, 2021

May 15, 2020

Notes receivable

289,000

Debt instrument, face amount

$ 249,540

$ 249,540

$ 249,540

HWH Ltd Note [Member]

Debt interest rate

18.00%

Maturity date

Dec. 31, 2021

Jan. 1, 2022

Debt instrument, face amount

$ 52,000

Notes Payable

$ 56,000

52,000

West Part Note [Member] | West Park Capital L L C [Member]

Debt interest rate

12.00%

Maturity date

Dec. 28, 2022

Debt instrument, face amount

$ 700,000

Notes Payable

680,000

700,000

SHRG and 1044PRO, LLC [Member]

Notes receivable

$ 193,000

Equity Method Investment, Ownership Percentage

10.00%

Long-Term Line of Credit

$ 250,000

Debt instrument, face amount

204,879

Gain (Loss) on Extinguishment of Debt

$ 115,000

Wuurii Commerce Inc [Member]

Debt interest rate

8.00%

Notes receivable

895,000

Debt instrument, face amount

$ 892,500

Notes receivable, current

446,000

Farah S Khan [Member]

Debt interest rate

6.00%

Notes receivable

$ 101,000

Debt instrument, face amount

$ 100,000

Schedule of Cash and Marketable

Schedule of Cash and Marketable Securities by Significant Investment Category (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 74,017,000	$ 73,929,000
Unrealized Gain/(Loss)	2,927,000	1,544,000
Fair Value	76,944,000	75,473,000
Cash and Cash Equivalents	53,811,000	56,595,000
Current Marketable Securities	18,435,000	14,537,000
Investments	4,698,000	4,341,000
Fair Value, Inputs, Level 2 [Member] | Convertible Securities [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	1,023,000	1,023,000
Unrealized Gain/(Loss)	357,000
Fair Value	1,380,000	1,023,000
Cash and Cash Equivalents
Current Marketable Securities
Investments	1,380,000	1,023,000
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	3,318,000	3,318,000
Unrealized Gain/(Loss)
Fair Value	3,318,000	3,318,000
Cash and Cash Equivalents
Current Marketable Securities
Investments	3,318,000	3,318,000
Cash [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	48,799,000	50,286,000
Unrealized Gain/(Loss)
Fair Value	48,799,000	50,286,000
Cash and Cash Equivalents	48,799,000	50,286,000
Current Marketable Securities
Investments
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	5,012,000	6,309,000
Unrealized Gain/(Loss)
Fair Value	5,012,000	6,309,000
Cash and Cash Equivalents	5,012,000	6,309,000
Current Marketable Securities
Investments
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	15,865,000	12,993,000
Unrealized Gain/(Loss)	2,570,000	1,544,000
Fair Value	18,435,000	14,537,000
Cash and Cash Equivalents
Current Marketable Securities	18,435,000	14,537,000
Investments

Acquisitions (Details Narrative

Acquisitions (Details Narrative)

Jan. 24, 2022$ / sharesshares

Dec. 21, 2021USD ($)

Nov. 04, 2021USD ($)

Sep. 09, 2021USD ($)$ / sharesshares

Jun. 18, 2021USD ($)$ / sharesshares

Mar. 31, 2022USD ($)$ / shares

Mar. 31, 2021USD ($)

Dec. 21, 2021USD ($)

Dec. 31, 2021$ / shares

Dec. 31, 2021ft²

Dec. 31, 2021a

Dec. 23, 2021

Sep. 30, 2021USD ($)

Aug. 21, 2020

Jul. 31, 2020

Jun. 18, 2020ft²

Mar. 03, 2020

Oct. 31, 2017$ / shares

Business Acquisition [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.25%

Price per share | $ / shares

$ 0.15

Area of Land

40,000

13.62

Net Income (Loss) Attributable to Parent

$ (8,048,000)

$ (3,981,000)

Net Income (Loss) Attributable to Noncontrolling Interest

$ (903,000)

(31,000)

Common Stock, Par or Stated Value Per Share | $ / shares

$ 0.02

$ 0.02

Minimum [Member]

Business Acquisition [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.25%

AMRE Shelton LLC [Member]

Business Acquisition [Line Items]

Payments to Acquire Businesses, Net of Cash Acquired

$ 7,150,000

Investment facility allocated

4,640,000

Real estate allocated price

1,600,000

Land improvements

325,000

Intangible asset

$ 585,000

Finite-Lived Intangible Asset, Useful Life

3 years

[custom:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesEarnOutDue-0]

$ 1,500,000

AMRE Life Care Portfolio LLC [Member]

Business Acquisition [Line Items]

Payments to Acquire Businesses, Net of Cash Acquired

$ 62,000,000

Investment facility allocated

32,100,000

Real estate allocated price

12,100,000

Land improvements

1,500,000

Intangible asset

$ 15,901,000

AMRE Winter Haven LLC [Member]

Business Acquisition [Line Items]

Payments to Acquire Businesses, Net of Cash Acquired

$ 4,500,000

Investment facility allocated

3,200,000

$ 3,200,000

Real estate allocated price

1,000,000

1,000,000

Land improvements

222,000

222,000

Intangible asset

$ 29,000

$ 29,000

Finite-Lived Intangible Asset, Useful Life

5 years

Net Income (Loss) Attributable to Parent

$ 1,613,000

58,000

Net Income (Loss) Attributable to Noncontrolling Interest

161,000

22,000

Sharing Services Global Corp [Member]

Business Acquisition [Line Items]

Ownership percent

58.00%

AMRE Asset Management Inc. [Member]

Business Acquisition [Line Items]

Ownership percent

52.50%

American Medical REIT Inc. [Member]

Business Acquisition [Line Items]

Ownership percent

93.00%

Unsecured Debt

$ 200,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Area of Land | ft²

40,000

American Medical REIT Inc. [Member] | Common Class A [Member]

Business Acquisition [Line Items]

Number of shares issued on acquisition | shares

264,525

Price per share | $ / shares

$ 10

Stock issued for acquisition, values

$ 2,645,250

Additional common stock shares acquired | shares

264,525

Equity interest percentage

93.00%

AMRE Life Care Portfolio LLC [Member] | Minimum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

1 year

AMRE Life Care Portfolio LLC [Member] | Maximum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

11 years

Impact BioMedical, Inc. [Member]

Business Acquisition [Line Items]

Net Income (Loss) Attributable to Parent

614,000

420,000

Net Income (Loss) Attributable to Noncontrolling Interest

67,000

$ 9,000

Impact BioMedical, Inc. [Member] | Minimum [Member]

Business Acquisition [Line Items]

Ownership percent

63.60%

Impact BioMedical, Inc. [Member] | Maximum [Member]

Business Acquisition [Line Items]

Ownership percent

100.00%

American Pacific Bancorp [Member]

Business Acquisition [Line Items]

Ownership percent

2.00%

Equity interest percentage

53.00%

Net Income (Loss) Attributable to Parent

547,000

Net Income (Loss) Attributable to Noncontrolling Interest

257,000

Business Acquisition, Equity Interest Issued or Issuable, Value Assigned

$ 40,000,000

Stock Issued During Period, Shares, New Issues | shares

6,666,700

Business Acquisition, Share Price | $ / shares

$ 6

General and Administrative Expense

$ 36,000

American Pacific Bancorp [Member] | Common Class A [Member]

Business Acquisition [Line Items]

Common Stock, Par or Stated Value Per Share | $ / shares

$ 0.01

Sharing Service Global Corp[Member]

Business Acquisition [Line Items]

Ownership percent

20.00%

Net Income (Loss) Attributable to Parent

7,364,000

Net Income (Loss) Attributable to Noncontrolling Interest

$ 2,579,000

Sharing Service Global Corp[Member] | Warrant [Member]

Business Acquisition [Line Items]

Ownership percent

65.00%

Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised | shares

50,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.0001

Investments (Details Narrative)

Investments (Details Narrative) - USD ($)	Jul. 22, 2021	May 13, 2021	Apr. 02, 2021	Mar. 18, 2021	Mar. 15, 2021	Dec. 30, 2020	Dec. 19, 2020	Sep. 10, 2020	Oct. 10, 2019	Feb. 28, 2022	Sep. 30, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Jun. 18, 2021	Oct. 31, 2017
Warrants percentage												7.00%
Unrealized Gain (Loss) on Investments												$ 2,927,000			$ 1,544,000
Debt Instrument, Interest Rate, Stated Percentage																4.25%
Investments												4,698,000		$ 4,341,000	4,341,000
Gain (Loss) on Investments												424,000	$ (1,077,000)
Stock Issued During Period, Value, New Issues												1,858,000	61,068,000
Investments equity method												$ 1,193,000		1,080,000	1,080,000
Shares Issued, Price Per Share																	$ 0.15
Vivacitas Agreement [Member]
Equity method investment, ownership percentage												16.00%
Share-based compensation arrangement by share-based payment award, options, exercises in period	1,000,000
Stock issued during period, value, stock options exercised	$ 1,000,000
Security Purchase Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage											10.00%
Debt Instrument, Maturity Date											Sep. 9, 2024
Investments equity method											$ 1,400,000
Convertible Notes Payable											1,400,000
[custom:OriginationFee]											$ 500,000
Security Purchase Agreement [Member] | GTNW [Member]
Unrealized Gain (Loss) on Investments												$ 357,000,000,000			3,700,000,000,000
Stock Issued During Period, Shares, New Issues											154,173
Membership Unit Purchase Agreement [Member]
Equity method investment, ownership percentage											30.75%
Stock Issued During Period, Value, Acquisitions														1,537,000
Impairment of investment												1,500,000
Common Stock [Member]
Stock Issued During Period, Value, New Issues												$ 98,000	$ 436,000
Stock Issued During Period, Shares, New Issues										44,619,423		4,881,000	21,834,000
BMI Capital International LLC [Member]
Equity method investment, ownership percentage								24.90%
Investments equity method												$ 49,000
Impact Oncology PTE Ltd [Member]
Options to purchase additional shares				250,000
Business combination, consideration transferred				$ 2,480,000
Sentinel Brokers Company Inc [Member]
Investments		$ 750,000									$ 1,050,000
Equity method investment, ownership percentage		24.90%										24.90%
Outstanding membership interest		50.10%
Business combination, consideration transferred		$ 300,000
Outstanding remaining membership interest		25.00%
Additional membership interest		50.10%
Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage																4.25%
Minimum [Member] | BMI Capital International LLC [Member]
Equity method investment, ownership percentage													20.00%
Alset International Limited [Member]
Investment Owned, Balance, Shares												127,179,311
Singapore eDevelopment Limited [Member]
Marketable Securities												$ 4,604,000		$ 4,909,000	4,909,000
Unrealized Gain (Loss) on Investments												305,000	$ 967,000
Century TBD Holdings, LLC [Member]
Convertible Debt									$ 500,000
Debt Instrument, Interest Rate, Stated Percentage									6.00%
Debt Instrument, Maturity Date									Oct. 9, 2021
Debt Instrument, Periodic Payment															$ 537,000
Century TBD Holdings, LLC [Member] | Maximum [Member]
Convertible Debt									$ 500,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger									19.80%
West Park Capital Inc [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger						7.50%
Investments												5,000
Gain (Loss) on Investments												$ 370
DSS Securities, Inc. [Member]
Equity method investment, ownership percentage								14.90%
Stock Issued During Period, Value, New Issues								$ 100,000
Outstanding membership interest								10.00%
Acquistion description												On or about August 28, 2020, the Company’s wholly owned subsidiary, DSS Securities, Inc. entered into a corporate venture to form and operate a real estate title agency, under the name of Alset Title Company, Inc, a Texas corporation (“ATC”). DSS Securities, Inc. shall own 70% of this venture with the other two shareholders being attorneys necessary to the state application and permitting process. ATC have initiated or have pending applications to do business in a number of states, including Texas, Tennessee, Connecticut, Florida, and Illinois. For the purpose of organization and the state application process, the Company’s CEO, who is a licensed attorney, has a stated non-compensated 15% ownership interest in the venture. There was minimal activity for the three months ended March 31, 2022
BioMed Technologies Asia Pacific Holdings Limited [Member]
Equity method investment, ownership percentage							4.99%
Stock Issued During Period, Value, New Issues							$ 632,000
Stock Issued During Period, Shares, New Issues							525
Vivacitas Oncology Inc [Member]
Stock Issued During Period, Shares, New Issues					500,000
Options to purchase additional shares					1,500,000
Shares Issued, Price Per Share					$ 1
Additional price per share					$ 1
Sale of Stock, Description of Transaction			Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021 and March 31, 2022.
Vivacitas Oncology Inc [Member] | Common Stock [Member]
Options to purchase additional shares					500,000
Shares Issued, Price Per Share					$ 1
Impact Oncology PTE Ltd [Member]
Investment Owned, Balance, Shares				2,480,000

Short-Term and Long-Term Debt (

Short-Term and Long-Term Debt (Details Narrative)

Mar. 17, 2022USD ($)

Nov. 30, 2021USD ($)

Nov. 02, 2021USD ($)

Oct. 13, 2021USD ($)

Jun. 18, 2021USD ($)

Jun. 18, 2021USD ($)

Oct. 31, 2017USD ($)$ / sharesshares

Mar. 31, 2022USD ($)

Dec. 31, 2021USD ($)

Dec. 31, 2021ft²

Dec. 31, 2021a

Sep. 30, 2021

May 20, 2021USD ($)

Mar. 16, 2021USD ($)

Dec. 31, 2020USD ($)

Jun. 18, 2020ft²

Mar. 02, 2020USD ($)$ / shares

Dec. 31, 2019USD ($)

Short-Term Debt [Line Items]

Principal amount

$ 6,155,000

$ 6,155,000

$ 50,000

Debt interest rate

4.25%

4.25%

Debt Instrument, Term

25 years

5 years

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 2,829,000

$ 2,829,000

Area of Land

40,000

13.62

Long-Term Debt, Current Maturities

$ 6,835,000

$ 3,916,000

Conversion of Stock, Shares Converted | shares

333,333

Warrants to purchase | shares

333,333

Shares Issued, Price Per Share | $ / shares

$ 0.15

Maximum [Member]

Short-Term Debt [Line Items]

Principal amount

$ 5,105,000

$ 5,105,000

Minimum [Member]

Short-Term Debt [Line Items]

Debt interest rate

4.25%

4.25%

American Medical REIT Inc. [Member]

Short-Term Debt [Line Items]

Principal amount

$ 111,000

Debt interest rate

8.00%

Area of Land | ft²

40,000

AMRE Shelton LLC [Member]

Short-Term Debt [Line Items]

Debt Instrument, Description

AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $

Long-Term Debt, Current Maturities

$ 191,000

$ 191,000

Long term debt

4,799,000

4,799,000

Deferred Costs

$ 185,000

$ 185,000

Paycheck Protection Program [Member]

Short-Term Debt [Line Items]

Principal amount

$ 110,000

Debt interest rate

1.00%

BMIC Loan [Member]

Short-Term Debt [Line Items]

Principal amount

$ 3,000,000

3,021,000

3,000,000

Debt Instrument, Description of Variable Rate Basis

interest to be charged at a variable rate to be adjusted at the maturity date

Debt maturity date

Oct. 12, 2022

Wilson Loan [Member]

Short-Term Debt [Line Items]

Principal amount

$ 3,000,000

3,000,000

Debt maturity date

Oct. 12, 2022

Alset Note [Member]

Short-Term Debt [Line Items]

Principal amount

$ 8,350,000

8,688,000

Debt interest rate

8.00%

Debt maturity, description

December 2023

Pinnacle Loan [Member]

Short-Term Debt [Line Items]

Principal amount

$ 2,990,000

138,000

Debt interest rate

4.28%

Long term debt

2,857,000

Debt maturity date

Mar. 7, 2024

Premier Packaging Bank Of America NA [Member]

Short-Term Debt [Line Items]

Principal amount

$ 3,710,000

3,339,000

Debt interest rate

4.63%

Debt financing amount

$ 3,700,000

Pinnacle Bank [Member]

Short-Term Debt [Line Items]

Principal amount

$ 40,300,000

39,448,000

Debt interest rate

4.28%

Deferred Costs

$ 1,002,000

Pinnacle Bank [Member] | LifeCare Agreement [Member]

Short-Term Debt [Line Items]

Long-Term Debt, Current Maturities

$ 39,940,000

Sharing Service Global Corp[Member]

Short-Term Debt [Line Items]

Principal amount

$ 100,000

Unsecured Promissory Note [Member] | American Medical REIT Inc. [Member]

Short-Term Debt [Line Items]

Principal amount

$ 200,000

Debt interest rate

8.00%

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5

Proceeds from warrant exercises

$ 200,000

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Lease Liability
2022	$ 513,000
2023	775,000
2024	54,000
2025	4,000
2026	2,000
2027
After
Total lease payments	1,348,000
Less: Imputed Interest	(26,000)
Present value of remaining lease payments	1,322,000
Current	540,000	$ 393,000
Noncurrent	$ 782,000	$ 120,000
Operating Lease, Weighted Average Remaining Lease Term	3 years 6 months
Weighted-average discount rate	4.20%

Lease Liability (Details Narrat

Lease Liability (Details Narrative)	3 Months Ended
	Mar. 31, 2022USD ($)
Maximum [Member]
Operating lease term	1 year
Operating lease payment	$ 78,000
Minimum [Member]
Operating lease term	5 years
Operating lease payment	$ 61,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Nov. 12, 2021	Mar. 26, 2021	Feb. 15, 2021	Apr. 30, 2019
Maiden Biosciences Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Loss contingency, allegations			2019 in favor of Decentralized and HWH, totaling approximately $800,000. Maiden, a 2020 default judgment creditor of RBC, in the principal amount of $4,329,000, now complains about those notes, the funding of those notes, the subsequent default of those notes by RBC, and HWH and Decentralized’s subsequent Article 9 foreclosure or deed-in-lieu debt conveyances. In the instant lawsuit, Maiden asserts claims against Defendants for unjust enrichment, fraudulent transfer under the Texas Uniform Fraudulent Transfer Act, and violation of the Racketeer Influenced and Corrupt Organizations Act. Maiden also seeks a judgment from the court declaring: “(1) Defendants lacked a valid security interest in RBC and RBC Subsidiaries’ assets and therefore lacked the authority to sell the assets during the public foreclosure sale; (2) Defendant Heuszel’s low bid at the public foreclosure sale was invalid and void; (3) the public foreclosure sale was conducted in a commercially unreasonable manner; and (4) Defendants do not have the legal authority to transfer RBC and RBC’s Subsidiaries assets to Heuszel and HWH.” Maiden seeks to recover from Defendants: (1) treble damages or, alternatively, damages in the amount of their underlying judgment plus the other creditors’ claims or the value of the assets transferred, whichever is less, plus punitive or exemplary damages; (2) pre- and post-judgment interest; and (3) attorneys’ fees and cost
Jeffrey Ronaldi [Member]
Defined Benefit Plan Disclosure [Line Items]
[custom:ReimbursementOfLegalFees]	$ 121,672.51	$ 160,896.25
Legal Fees	$ 281,443.76	$ 159,771.25
Jeffrey Ronaldi [Member] | 2017 Employment Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Loss contingency, allegations				In April 2019 DSS commenced an action in New York State Supreme Court, Monroe County, Index No. E2019003542, against Jeffrey Ronaldi, our former Chief Executive Officer. This New York action seeks a declaratory judgment that, contrary to informal claims made by him, Mr. Ronaldi’s employment agreement with us expired by its terms and that he is not entitled to any cash bonuses or other unpaid amounts. The lawsuit also seeks an injunction against Mr. Ronaldi from interfering with any of DSS’ IP litigation. Mr. Ronaldi subsequently commenced an action against DSS in the Superior Court of California, County of San Diego, on November 8, 2019, under case number 37-2019-00059664-CU-CO-CTL, in which he alleged that DSS terminated his employment in April 2019 in order to avoid paying him certain employment-related amounts. DSS was successful in dismissing the California case and consolidating it with the action pending in Monroe County, New York. Mr. Ronaldi asserted counterclaims in the Monroe County, New York action similar to those he originally brought in California. Mr. Ronaldi claims that his termination violated an alleged employment agreement or implied-in-fact employment agreement and that he should have remained employed through 2019. Mr. Ronaldi seeks to recover: (i) $144,658 in wages from April 11, 2019 through December 31, 2019; (ii) $769 in alleged unpaid based salary for time worked before April 11, 2019; (iii) $15,385 in alleged paid time off compensation; (iv) $3,077 in alleged unpaid sick time compensation; (v) $26,077 in waiting-time penalties; (vi) $91,000 in unspecified expense reimbursement; (vii) $300,000 in alleged cash bonuses ($100,000 per year) based on DSS’s performance in 2017, 2018 and 2019; and (viii) a $450,000 performance bonus based on the result of certain alleged net proceeds from patent infringement litigation. He further claims an interest in any recovery in DSS Technology Management v. Apple, Inc., Case No. 4:14-cf05330-HSG. The court recently ordered Mr. Ronaldi to produce several categories of documents that he sought to withhold. Discovery is ongoing

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Mar. 10, 2022	Sep. 03, 2021	Feb. 28, 2022	Mar. 31, 2022	Mar. 31, 2021	Oct. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares Issued, Price Per Share						$ 0.15
Value of shares consideration				$ 1,858,000	$ 61,068,000
Basic and diluted loss per share				$ (0.10)	$ (0.21)
Stock Based Compensation Expenses [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based payment arrangement, expense				$ 4,000
Basic and diluted loss per share				$ 0.01
Heng Fai Ambrose Chan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock	894,084
Value of shares consideration	$ 340,000
AEI Subscription Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares Issued, Price Per Share			$ 0.3810
Supplemental Deferred Purchase Price			$ 17,000,000
Payments for (Proceeds from) Previous Acquisition			$ 1,519,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock			44,619,423	4,881,000	21,834,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans		3,986,877
Value of shares consideration				$ 98,000	$ 436,000

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 1,378,000	$ 20,000
Non-cash investing and financing activities:
Termination of right of use lease asset		(744,000)
Termination of right of use lease liability		744,000
Debt conversion to equity	840,000
Shares issued for accrued bonus	$ 340,000

Schedule of Operations by Repor

Schedule of Operations by Reportable Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 12,304,000	$ 4,469,000
Depreciation and amortization	3,266,000	514,000
Interest expense	1,378,000	20,000
Stock based compensation	4,000	7,000
Impairment of goodwill
Net income (loss) from continuing operations	(8,951,000)	(4,062,000)
Capital expenditures	942,000	72,000
Identifiable assets	281,859,000	141,823,000
Operating Segments [Member] | Product Packaging [Member]
Segment Reporting Information [Line Items]
Revenue	3,569,000	3,861,000
Depreciation and amortization	180,000	116,000
Interest expense	24,000	19,000
Stock based compensation	1,000	1,000
Impairment of goodwill
Net income (loss) from continuing operations	(42,000)	218,000
Capital expenditures	923,000	66,000
Identifiable assets	23,371,000	22,567,000
Operating Segments [Member] | Commercial Banking [Member]
Segment Reporting Information [Line Items]
Revenue	129,000
Depreciation and amortization
Interest expense
Stock based compensation
Impairment of goodwill
Net income (loss) from continuing operations	181,000
Capital expenditures
Identifiable assets	57,259,000
Operating Segments [Member] | Direct Marketing Online Sales [Member]
Segment Reporting Information [Line Items]
Revenue	6,932,000	608,000
Depreciation and amortization	49,000	44,000
Interest expense	687,000
Stock based compensation
Impairment of goodwill
Net income (loss) from continuing operations	(4,486,000)	(1,799,000)
Capital expenditures	2,000	6,000
Identifiable assets	45,788,000	18,892,000
Operating Segments [Member] | Biotechnology [Member]
Segment Reporting Information [Line Items]
Revenue
Depreciation and amortization	278,000	278,000
Interest expense
Stock based compensation
Impairment of goodwill
Net income (loss) from continuing operations	(616,000)	(698,000)
Capital expenditures
Identifiable assets	56,276,000	51,158,000
Operating Segments [Member] | Securities [Member]
Segment Reporting Information [Line Items]
Revenue	1,674,000
Depreciation and amortization	2,685,000
Interest expense	667,000
Stock based compensation
Impairment of goodwill
Net income (loss) from continuing operations	(2,508,000)
Capital expenditures	13,000
Identifiable assets	85,178,000
Operating Segments [Member] | Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue
Depreciation and amortization	74,000	76,000
Interest expense		1,000
Stock based compensation	3,000	6,000
Impairment of goodwill
Net income (loss) from continuing operations	(1,480,000)	(1,783,000)
Capital expenditures	4,000
Identifiable assets	$ 13,987,000	$ 49,206,000

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Total Printed Products	$ 3,569,000	$ 3,861,000
Direct Marketing	6,932,000	608,000
Total Rental Income	1,663,000
Total Management fee income	11,000
Total Investment fee income	129,000
Packaging Printing and Fabrication [Member]
Segment Reporting Information [Line Items]
Total Printed Products	3,516,000	3,720,000
Commercial and Security Printing [Member]
Segment Reporting Information [Line Items]
Total Printed Products	53,000	141,000
Direct Marketing Internet Sales [Member]
Segment Reporting Information [Line Items]
Direct Marketing	6,932,000	608,000
Rental Income [Member]
Segment Reporting Information [Line Items]
Total Rental Income	1,663,000
Management Fee Income [Member]
Segment Reporting Information [Line Items]
Total Management fee income	11,000
Net Investment Income [Member]
Segment Reporting Information [Line Items]
Total Investment fee income	$ 129,000

Segment Information (Details Na

Segment Information (Details Narrative)	3 Months Ended
	Mar. 31, 2022Segments
Segment Reporting [Abstract]
Number of operating segments	5